In Vivo Method | Cmax | Tmax | AUC∞ | CLb/F | MRT |
---|---|---|---|---|---|
µM | h | µM·h | ml/min per kg | h | |
ABT-treated mice | |||||
Control (no ABT) | 118 ± 4 | 0.3 ± 0 | 138 ± 5 | 12.8 ± 0.5 | 0.8 ± 0.0 |
ABT bolus (s.c.) | |||||
2 h prior | 129 ± 7 | 0.8 ± 0 | 1147 ± 312 (↑ 8.3-fold)** | 1.6 ± 0.4* | **4.3 ± 0.3* |
24 h prior | 85 ± 5* | 0.4 ± 0.4 | 198 ± 27 (↑ 1.4-fold) | 9.1 ± 1.4 | 1.7 ± 0.2** |
ABT pump (s.c.) | |||||
24 h prior | 135 ± 3** | 0.3 ± 0 | 1265 ± 184 (↑ 9.1-fold)* | 1.4 ± 0.2* | **4.8 ± 0.3* |
120 h prior | 98 ± 30 | 0.4 ± 0.4 | 799 ± 232 (↑ 5.8-fold)** | 2.4 ± 0.8* | **4.5 ± 0.1* |
HRN mice | |||||
Wild-type C57/BL6 | 90 ± 7 | 0.2 ± 0.1 | 82 ± 6 | 21.7 ± 1.6 | 0.5 ± 0.0 |
HRN | 114 ± 4** | 0.2 ± 0.1 | 836 ± 47 (↑ 10.1-fold)* | 2.1 ± 0.1** | **4.3 ± 0.0* |
AUC, area under the concentration-time curve; CLb, total clearance from blood; MRT, mean residence time.
↵* P < 0.01; **P < 0.05 (analysis of variance, Bonferroni) versus values in the control group.